Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 7;29(1):78–88. doi: 10.1089/ten.teb.2022.0094

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Kieran Joyce et al. 2023; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

PMC Copyright notice

FIG. 1. — Geographical overview of clinical trial activity investigating TEPs in each Member State according to the EU Clinical Trials register, analyzed on January 22, 2022. The geographical map represents all trial sites across EU states, where some trials contain multiple sites across states. “No. of trials by sponsor state/union” represents the number of individual trials funded by a sponsor in each named jurisdiction. Sponsor state, trial phase, sponsor status, and trial status reflect individual trials with unique EudraCT numbers. Funding sources for TEP clinical trials are divided into sponsors located in EU and non-EU states. Two trials sponsored by the EU through the European Commission and Horizon 2020 listed the EU as the sponsor and thus no state is given. However, while UK is no longer in the EU, it has been included in this graph to accurately represent clinical activity over the last 12 years. Trial-phase status is based on the most recent updated list in the EU Clinical Trials Register. Phase I trials are not publicly available in the EudraCT database, except those including pediatric populations. “Other” in trial status includes two halted trials and one restarted trial. EU, European Union; TEP, tissue-engineered product; UK, United Kingdom. Color images are available online.